Medicus Pharma Says INAD File No.013880 Received Minor Use In Major Species Designation From FDA For Its Dissolvable D-MNA To Treat External Squamous Cell Carcinoma In Horses
Medicus Pharma Says INAD File No.013880 Received Minor Use In Major Species Designation From FDA For Its Dissolvable D-MNA To Treat External Squamous Cell Carcinoma In Horses
Medicus Pharma表示，INAD檔案號013880已獲得FDA的主要動物種類中的小規模使用認證，用於治療馬匹的外部鱗狀細胞癌。
The company received a notification from the FDA on December 9th 2024.
公司於2024年12月9日收到了FDA的通知。
MUMS is a status similar to Orphan Drug status for human drugs. It entitles the company to an extended 7-year period of exclusive marketing following approval or conditional approval, provided that the company meets all requirements for maintaining the designation.
MUMS是一種類似於人用藥品的孤兒藥狀態的認證，允許公司在獲批或條件獲批後享有長達7年的獨佔市場資格，前提是公司滿足所有保持該認證的要求。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
資訊熱榜
更新時間